CO2019002692A2 - Nuevos derivados de isoxazolil éter como pam de gaba a alfa5. - Google Patents
Nuevos derivados de isoxazolil éter como pam de gaba a alfa5.Info
- Publication number
- CO2019002692A2 CO2019002692A2 CONC2019/0002692A CO2019002692A CO2019002692A2 CO 2019002692 A2 CO2019002692 A2 CO 2019002692A2 CO 2019002692 A CO2019002692 A CO 2019002692A CO 2019002692 A2 CO2019002692 A2 CO 2019002692A2
- Authority
- CO
- Colombia
- Prior art keywords
- alpha5
- gaba
- pam
- new derivatives
- isoxazolyl
- Prior art date
Links
- LRJJZSXDNXHKQV-UHFFFAOYSA-N 3-(1,2-oxazol-3-yloxy)-1,2-oxazole Chemical class C1=CON=C1OC=1C=CON=1 LRJJZSXDNXHKQV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La invención proporciona compuestos novedosos que tienen la fórmula general (I), en donde R1, R2, R3, R4, R5, R6, X, Y y Z es tal como se describe en el presente documento, composiciones que incluye los compuestos y métodos de uso de los compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16202889 | 2016-12-08 | ||
| PCT/EP2017/081768 WO2018104419A1 (en) | 2016-12-08 | 2017-12-07 | New isoxazolyl ether derivatives as gaba a alpha5 pam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019002692A2 true CO2019002692A2 (es) | 2019-04-12 |
Family
ID=57530563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0002692A CO2019002692A2 (es) | 2016-12-08 | 2019-03-26 | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5. |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US11091471B2 (es) |
| EP (1) | EP3551627B1 (es) |
| JP (1) | JP7084405B2 (es) |
| KR (1) | KR102564643B1 (es) |
| CN (2) | CN109923113B (es) |
| AR (1) | AR110498A1 (es) |
| AU (1) | AU2017373734B2 (es) |
| BR (1) | BR112019006571A2 (es) |
| CA (1) | CA3040024A1 (es) |
| CL (1) | CL2019001458A1 (es) |
| CO (1) | CO2019002692A2 (es) |
| CR (1) | CR20190268A (es) |
| DK (1) | DK3551627T3 (es) |
| ES (1) | ES2910110T3 (es) |
| HR (1) | HRP20220468T1 (es) |
| HU (1) | HUE058355T2 (es) |
| IL (1) | IL267054B (es) |
| LT (1) | LT3551627T (es) |
| MA (1) | MA48594B1 (es) |
| MX (1) | MX388725B (es) |
| MY (1) | MY200641A (es) |
| PE (1) | PE20191156A1 (es) |
| PH (1) | PH12019500664B1 (es) |
| PL (1) | PL3551627T3 (es) |
| PT (1) | PT3551627T (es) |
| RS (1) | RS63106B1 (es) |
| SI (1) | SI3551627T1 (es) |
| TW (1) | TWI642666B (es) |
| UA (1) | UA125524C2 (es) |
| WO (1) | WO2018104419A1 (es) |
| ZA (1) | ZA201902225B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY200641A (en) | 2016-12-08 | 2024-01-08 | Hoffmann La Roche | New isoxazolyl ether derivatives as gaba a alpha5 pam |
| MX2020013518A (es) | 2018-06-13 | 2021-02-26 | Hoffmann La Roche | Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) del receptor de acido gamma-aminobutirico a alfa5 (gaba a alfa5). |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| WO2021191837A1 (en) * | 2020-03-26 | 2021-09-30 | Richter Gedeon Nyrt. | 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa α5 receptor modulators |
| PE20221836A1 (es) * | 2020-03-26 | 2022-11-29 | Richter Gedeon Nyrt | Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5 |
| CA3216863A1 (en) | 2021-05-05 | 2022-11-10 | University College Cardiff Consultants Limited | Heteroaryl compounds useful in the treatment of cognitive disorders |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| WO2023247389A1 (en) | 2022-06-20 | 2023-12-28 | F. Hoffmann-La Roche Ag | Crystalline forms of 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4- yl)methoxy)-n-(tetrahydrapyran-4-yl)pyridazine-3-carboxamide |
| WO2024088928A1 (en) | 2022-10-25 | 2024-05-02 | F. Hoffmann-La Roche Ag | Process for manufacturing alogabat |
| WO2024223450A1 (en) | 2023-04-24 | 2024-10-31 | F. Hoffmann-La Roche Ag | Tablet comprising 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl)methoxy)- n-(tetrahydrapyran-4-yl)pyridazine-3-carboxamide |
| TW202448433A (zh) * | 2023-06-05 | 2024-12-16 | 大陸商武漢人福創新藥物研發中心有限公司 | 作為α5-GABAA受體調節劑的雜環化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008241604A1 (en) | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | Xanthine compounds having a positive allosteric GABAB receptor modulator effect |
| PT2227467E (pt) * | 2007-12-04 | 2015-03-02 | Hoffmann La Roche | Derivados de isoxazol-piridina |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8222246B2 (en) * | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| AU2010244553A1 (en) | 2009-05-05 | 2011-12-01 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
| EP2635277B1 (en) | 2010-11-05 | 2018-12-19 | F.Hoffmann-La Roche Ag | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| ES3016782T3 (en) * | 2011-09-15 | 2025-05-09 | Cincor Pharma Inc | New dihydroquinoline-2-one derivatives |
| AU2016308717A1 (en) | 2015-08-17 | 2018-01-25 | Lupin Limited | Heteroaryl derivatives as PARP inhibitors |
| UA124529C2 (uk) | 2016-01-08 | 2021-10-05 | Аркус Байосайєнсіз, Інк. | Модулятори екто-5-нуклеотидази та їх застосування |
| AR107321A1 (es) | 2016-01-08 | 2018-04-18 | Celgene Corp | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos |
| MY200641A (en) | 2016-12-08 | 2024-01-08 | Hoffmann La Roche | New isoxazolyl ether derivatives as gaba a alpha5 pam |
-
2017
- 2017-12-07 MY MYPI2019001529A patent/MY200641A/en unknown
- 2017-12-07 BR BR112019006571-7A patent/BR112019006571A2/pt active Search and Examination
- 2017-12-07 JP JP2019530755A patent/JP7084405B2/ja active Active
- 2017-12-07 PT PT178166302T patent/PT3551627T/pt unknown
- 2017-12-07 HR HRP20220468TT patent/HRP20220468T1/hr unknown
- 2017-12-07 WO PCT/EP2017/081768 patent/WO2018104419A1/en not_active Ceased
- 2017-12-07 DK DK17816630.2T patent/DK3551627T3/da active
- 2017-12-07 CR CR20190268A patent/CR20190268A/es unknown
- 2017-12-07 CN CN201780069758.2A patent/CN109923113B/zh active Active
- 2017-12-07 LT LTEPPCT/EP2017/081768T patent/LT3551627T/lt unknown
- 2017-12-07 TW TW106142872A patent/TWI642666B/zh active
- 2017-12-07 PH PH1/2019/500664A patent/PH12019500664B1/en unknown
- 2017-12-07 AR ARP170103429A patent/AR110498A1/es unknown
- 2017-12-07 CN CN202311216893.9A patent/CN117285525A/zh active Pending
- 2017-12-07 MA MA48594A patent/MA48594B1/fr unknown
- 2017-12-07 MX MX2019006696A patent/MX388725B/es unknown
- 2017-12-07 PE PE2019001006A patent/PE20191156A1/es unknown
- 2017-12-07 EP EP17816630.2A patent/EP3551627B1/en active Active
- 2017-12-07 SI SI201731124T patent/SI3551627T1/sl unknown
- 2017-12-07 RS RS20220321A patent/RS63106B1/sr unknown
- 2017-12-07 UA UAA201907047A patent/UA125524C2/uk unknown
- 2017-12-07 CA CA3040024A patent/CA3040024A1/en active Pending
- 2017-12-07 HU HUE17816630A patent/HUE058355T2/hu unknown
- 2017-12-07 PL PL17816630T patent/PL3551627T3/pl unknown
- 2017-12-07 AU AU2017373734A patent/AU2017373734B2/en active Active
- 2017-12-07 ES ES17816630T patent/ES2910110T3/es active Active
- 2017-12-07 KR KR1020197016011A patent/KR102564643B1/ko active Active
-
2019
- 2019-03-26 CO CONC2019/0002692A patent/CO2019002692A2/es unknown
- 2019-04-09 ZA ZA2019/02225A patent/ZA201902225B/en unknown
- 2019-05-29 CL CL2019001458A patent/CL2019001458A1/es unknown
- 2019-06-03 IL IL267054A patent/IL267054B/en unknown
- 2019-06-05 US US16/432,584 patent/US11091471B2/en active Active
-
2021
- 2021-07-16 US US17/378,410 patent/US20220411415A1/en not_active Abandoned
-
2024
- 2024-02-28 US US18/590,606 patent/US20240279218A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019002692A2 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5. | |
| MX2021005714A (es) | Nuevos compuestos heterociclicos. | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| CY1120188T1 (el) | ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6 | |
| MX2018003130A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos. | |
| CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| CU24309B1 (es) | Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen | |
| CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
| BR112014030473A2 (pt) | novo diazaespirocicloalcano e azaespirocicloalcano | |
| NI201500130A (es) | 2-azabiciclo sustituidos y su uso como moduladores del receptor de orexina | |
| CL2017002856A1 (es) | Compuestos de tioéter como inhibidores de la nitrificación | |
| CR20160459A (es) | Nuevos derivados de piridina | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| CR20180298A (es) | Nuevos derivados de fenilo | |
| CL2020002217A1 (es) | Uso de alcoxipirazoles como inhibidores de la nitrificación | |
| CR20160448A (es) | Nuevos derivados de piridina | |
| BR112018001726A2 (pt) | inibidores do vírus sincicial respiratório | |
| MX373636B (es) | Compuestos de azetidiniloxifenilpirrolidina. | |
| CL2020003214A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 | |
| UY37968A (es) | Derivados del tetrazolilpropilo y su uso como fungicidas | |
| AR095353A1 (es) | Compuesto | |
| CO2018007756A2 (es) | Nuevos derivados pirrolidina | |
| CL2019003236A1 (es) | Las sales de un compuesto y sus formas cristalinas. |